Global Home Global Home  
 
 

News

Date Title and Summary Additional Formats
Toggle Summary Petsmart® Launches The Microcynah® Family of Pet Healthcare Products for Dogs, Cats, Birds, Reptiles and Small Animals
PHOENIX and PETALUMA, Calif., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that PetSmart, Inc., the leading pet specialty retailer in North America, has launched the company’s MicrocynAH® family of animal healthcare products this
View HTML
Toggle Summary Sonoma Pharmaceuticals Reports Financial Results for Fiscal Third Quarter 2017
U.S. Product Revenue up 65%, Driven by Growth in U.S. Dermatology Sales Cash Position of $20.5 Million; More Than Fully Funded to Achieve EBITDA Breakeven  Income From Discontinued Operations of $15.5 Million and Net Income of $16.2 Million Due to the Sale of Latin America Assets   Conference Call
View HTML
Toggle Summary Sonoma Pharmaceuticals Appoints Marc Umscheid as Chief Strategy and Marketing Officer
PETALUMA, Calif., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced the appointment of Marc Umscheid as chief strategy and marketing officer.  Previously, Umscheid worked at the Clorox Company where he most recently served as senior
View HTML
Toggle Summary Sonoma Pharmaceuticals Announces Fiscal Third Quarter 2017 Financial Results and Conference Call
PETALUMA, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA, warrants SNOAW), today announced that the financial results for its fiscal third quarter 2017, ended December 31, 2016, will be released after the U.S. markets close on February 9, 2017.
View HTML
Toggle Summary With $19.5 Million In Coffers From Asset Sale, Sonoma Pharmaceuticals Sets Sights On Breakeven -- Secfilings.Com
REDONDO BEACH, CA--(Marketwired - Jan 26, 2017) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article examining Sonoma Pharmaceuticals' (NASDAQ: SNOA) recent sale of Latin American and
View HTML
Toggle Summary Oculus Innovative Sciences Reports Financial Results for Fiscal Second Quarter 2017
U.S. Product Revenue up 43%, Driven by Growth in U.S. Dermatology   Oculus Announced Sale of Latin America Assets for $19.5 Million in Cash (see separate press release, issued on October 31, 2016 )   Dermatology Prescriptions Up 17%, September 2016 Quarter over June 2016 Quarter Conference Call
View HTML
Toggle Summary Oculus Innovative Sciences Sells Latin America Business to Invekra S.A.P.I. de C.V. for $19.5 Million in Cash
Total cash consideration for sale of Latin American business (which is 30% of current Oculus revenue) exceeds Oculus' current market capitalization of $17 million U.S. Transaction further includes a 10-year annual payment of 3% on Latin American sales (excluding Mexico ) with a minimum of $250,000
View HTML
Toggle Summary Oculus Innovative Sciences Announces Fiscal Second Quarter 2017 Financial Results and Conference Call
PETALUMA, Calif. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. ( NASDAQ : OCLS, warrants OCLSW), today announced that the financial results for its fiscal second quarter 2017, ended September 30, 2016 , will be released after the U.S. markets close on November 10, 2016 .
View HTML
Toggle Summary Oculus Innovative Sciences Launches Lasercyn™ into U.S. Dermatology Market for Use Following Laser Procedures, Microdermabrasions and Chemical Peels
PETALUMA, Calif. , Aug. 30, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. ( NASDAQ : OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced the commercial
View HTML
Toggle Summary Oculus Innovative Sciences Receives U.S. FDA Approval for New Post-Dermal-Procedures Product for Removal of Foreign Material Including Microorganisms
PETALUMA, Calif. , Aug. 24, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. ( NASDAQ : OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care, today announced it has received a
View HTML